Recent developments in research
- New treatment for ROS1+ non-small cell lung cancer
- LCRF announces grant focused on curing EGFRmut+ lung cancers
- LCRF announces new research collaboration with Boehringer Ingelheim
- Accelerated approval for c-MET directed ADC
- 1-year updates from research grantees
- LCRF-funded work highlighted at AACR annual meeting
- Science Update | Spring 2025
- Inhibiting Tim-1 to enhance immunotherapy
- Science Made Simple: drug approval for NTRK
Recent FDA approvals
- Accelerated approval for c-MET directed ADC
- New FDA approval for EGFR exon 19 and exon 21 L858R
- FDA approves alectinib for ALK+ NSCLC
- Recent FDA approval of combined therapy for initial treatment of EGFR-mutated NSCLC
- FDA approves repotrectinib for patients with advanced ROS-1 fusion non-small cell lung cancer
- FDA grants accelerated approval to adagrasib for KRAS G12C-mutated NSCLC